American Association for Cancer Research
15357163mct120087-sup-fig_3_pdf_48kb.pdf (48.13 kB)

Supplementary Figure 3 from FcRL5 as a Target of Antibody–Drug Conjugates for the Treatment of Multiple Myeloma

Download (48.13 kB)
journal contribution
posted on 2023-04-03, 13:23 authored by Kristi Elkins, Bing Zheng, MaryAnn Go, Dionysos Slaga, Changchun Du, Suzie J. Scales, Shang-Fan Yu, Jacqueline McBride, Ruth de Tute, Andy Rawstron, Andrew S. Jack, Allen Ebens, Andrew G. Polson

PDF file - 48KB, In vivo efficacy of anti-FcRL5-MC-vc-PAB-MMAE in combination with bortezomib



Fc receptor-like 5 (FcRL5/FcRH5/IRTA2/CD307) is a surface protein expressed selectively on B cells and plasma cells. We found that FcRL5 was expressed at elevated levels on the surface of plasma cells from the bone marrow of patients diagnosed with multiple myeloma. This prevalence in multiple myeloma and narrow pattern of normal expression indicate that FcRL5 could be a target for antibody-based therapies for multiple myeloma, particularly antibody–drug conjugates (ADC), potent cytotoxic drugs linked to antibodies via specialized chemical linkers, where limited expression on normal tissues is a key component to their safety. We found that FcRL5 is internalized upon antibody binding, indicating that ADCs to FcRL5 could be effective. Indeed, we found that FcRL5 ADCs were efficacious in vitro and in vivo but the unconjugated antibody was not. The two most effective consisted of our anti-FcRL5 antibody conjugated through cysteines to monomethylauristatin E (MMAE) by a maleimidocaproyl-valine-citrulline-p-aminobenzyloxycarbonyl (MC-vcPAB) linker (anti-FcRL5-MC-vcPAB-MMAE) or conjugated via lysines to the maytansinoid DM4 through a disulfide linker (anti-FcRL5-SPDB-DM4). These two ADCs were highly effective in vivo in combination with bortezomib or lenalidomide, drugs in use for the treatment of multiple myeloma. These data show that the FcRL5 ADCs described herein show promise as an effective treatment for multiple myeloma. Mol Cancer Ther; 11(10); 2222–32. ©2012 AACR.

Usage metrics

    Molecular Cancer Therapeutics



    Ref. manager